TREA

88692176

Follow

Information

  • Trademark
  • 88692176
  • Serial Number
    88692176
  • Registration Number
    7082817
  • Filing Date
    November 14, 2019
    5 years ago
  • Registration Date
    June 20, 2023
    a year ago
  • Transaction Date
    January 28, 2025
    20 days ago
  • Status Date
    June 20, 2023
    a year ago
  • Published for Opposition Date
    April 04, 2023
    a year ago
  • Location Date
    January 28, 2025
    20 days ago
  • Status Code
    700
  • Current Location
    Historical data usage
    Employee Name
    REID, CAILE
  • Attorney Docket Number
    015343.00346
    Attorney Name
    Jason J. Mazur
  • Owners
Information
Mark Drawing Code
2
Case File Statements
  • GS0401: Contract manufacturing of clinical batches of pharmaceuticals; consulting services relating to pharmaceutical manufacturing and batch biological treatment batches
  • DM0000: The mark consists of a design element of overlapping arced lines with the bottom line in red and the top line in blue.
  • B00001: In the statement line 1,  Septodont Holding SAS, should be deleted, and, Septodont Holding, should be inserted.
  • GS0051: Pharmaceutical products namely, acne medication, allergy medication, antacids, anthelmintics, antiarrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medication, calcium channel blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives, pain relief medication, and topical and injectable pharmaceutical preparations for dental, endodontic and periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, bulimia nervosa, anorexia, and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical preparations for treatment of dry skin caused by pregnancy; pharmaceutical preparations for hydrating the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for the treatment of all of the foregoing diseases and conditions; disinfection systems, namely, all-purpose disinfectants
  • CC0000: The color(s) blue and red is/are claimed as a feature of the mark.
  • GS0351: Business consulting services relating to pharmaceutical manufacturing, clinical evaluation and testing, regulatory registration, stability studies, method development, formal stability, registration batches and commercial production; clinical trial services, namely, business and information management of clinical studies to fast track drug products to market
  • GS0451: Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; consulting services relating to pharmaceuticals in the field of regulatory compliance, namely, regulatory registration
  • GS0101: Drug delivery systems, consisting of needles, syringes, nasal spray bottles, injection devices, oral and nasal inhalation devices, patch pumps, and anesthetic delivery apparatus for medical purposes, but not for use in the fields of diabetes and obesity
  • GS0421: Pharmaceutical drug development services, namely, the formulation of new dosage forms and the reformulation of existing drug products; clinical trial services in the nature of conducting trials for others, namely, managing clinical studies to fast track drug products to market; consulting services relating to clinical testing, inspection, or research of pharmaceuticals; consulting services relating to conducting pharmaceutical stability studies and formal stability studies; consulting services relating to the development of chemical production methods; consulting services relating to registration batch research and commercial pharmaceutical products development
Case File Event Statements
  • 11/18/2019 - 5 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 11/20/2019 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 11/21/2019 - 5 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 2/19/2020 - 5 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 2/20/2020 - 4 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/20/2020 - 4 years ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/20/2020 - 4 years ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 3/16/2020 - 4 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 3/16/2020 - 4 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 3/16/2020 - 4 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 3/18/2020 - 4 years ago
    11 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 3/18/2020 - 4 years ago
    12 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 3/18/2020 - 4 years ago
    13 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 9/18/2020 - 4 years ago
    14 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 9/18/2020 - 4 years ago
    15 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 9/18/2020 - 4 years ago
    16 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 9/21/2020 - 4 years ago
    17 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 12/16/2020 - 4 years ago
    18 - ASSIGNED TO LIE Type: ALIE
  • 12/28/2020 - 4 years ago
    19 - ASSIGNED TO LIE Type: ALIE
  • 12/29/2020 - 4 years ago
    20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/1/2021 - 3 years ago
    26 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 7/1/2021 - 3 years ago
    27 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 7/1/2021 - 3 years ago
    25 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 12/29/2020 - 4 years ago
    21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/30/2020 - 4 years ago
    22 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 12/30/2020 - 4 years ago
    23 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 12/30/2020 - 4 years ago
    24 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 12/28/2021 - 3 years ago
    28 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 1/3/2022 - 3 years ago
    29 - ASSIGNED TO LIE Type: ALIE
  • 1/10/2022 - 3 years ago
    30 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/10/2022 - 3 years ago
    31 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/10/2022 - 3 years ago
    32 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 1/10/2022 - 3 years ago
    33 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 1/10/2022 - 3 years ago
    34 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 3/1/2022 - 2 years ago
    35 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 3/1/2022 - 2 years ago
    36 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 3/1/2022 - 2 years ago
    37 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 3/1/2022 - 2 years ago
    38 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 3/9/2022 - 2 years ago
    39 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/18/2022 - 2 years ago
    40 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 8/8/2022 - 2 years ago
    41 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 8/8/2022 - 2 years ago
    42 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 8/8/2022 - 2 years ago
    43 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 2/1/2023 - 2 years ago
    44 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 2/8/2023 - 2 years ago
    45 - ASSIGNED TO LIE Type: ALIE
  • 2/8/2023 - 2 years ago
    46 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 2/8/2023 - 2 years ago
    47 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/8/2023 - 2 years ago
    48 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/21/2023 - a year ago
    49 - PRIORITY ACTION WRITTEN Type: CPRA
  • 2/21/2023 - a year ago
    50 - PRIORITY ACTION E-MAILED Type: GPRA
  • 2/21/2023 - a year ago
    51 - NOTIFICATION OF PRIORITY ACTION E-MAILED Type: GPRN
  • 2/24/2023 - a year ago
    52 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/27/2023 - a year ago
    53 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/27/2023 - a year ago
    54 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/28/2023 - a year ago
    55 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 4/4/2023 - a year ago
    57 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/4/2023 - a year ago
    58 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/20/2023 - a year ago
    60 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 6/20/2023 - a year ago
    59 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 7/24/2024 - 6 months ago
    61 - TEAS SECTION 7 REQUEST RECEIVED Type: ES7R
  • 1/28/2025 - 20 days ago
    63 - CORRECTION UNDER SECTION 7 - PROCESSED Type: COC.
  • 1/18/2025 - a month ago
    62 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE
  • 3/15/2023 - a year ago
    56 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP